Overview


According to FutureWise analysis the market for chronic kidney disease diagnostics in 2023 is US$ 0.85 billion, and is expected to reach US$ 1.44 billion by 2031 at a CAGR of 6.7%.

Chronic kidney disease symptoms like blood in urine, swollen joints, foamy urine, etc are seldom noticed by patients resulting in progressive loss of kidney functions and ultimately renal failure. Delayed diagnosis, lack of sufficient epidemiological data, the significant cost involved in end-stage renal diseases as well as mild kidney diseases have resulted in a substantial need for chronic kidney disease diagnostics. Apart from physical examination by healthcare professionals, certain diagnostics like biopsy or procedures like blood and urine test provide vital stats and early signs about patients neurological, blood vessels and organ conditions. Based on such diagnostic results healthcare professionals can effectively control the kidney symptoms and avoid the progression of chronic kidney disease in their patients.

Factors boosting the chronic kidney disease diagnostics market:

  • Rising prevalence of kidney diseases
  • Increase in diabetic patients’ population
  • Investments into R D for kidney diseases diagnostic techniques
  • The ever-emerging healthcare sector
  • Extensive use of processed food containing excess potassium and
  • The technological advancements in the healthcare diagnostics sector

Besides increased susceptibility of the ageing population due to degrading immune system, diabetics, cardiovascular issues are expected to fuel the growth of the global chronic kidney diseases diagnostics market during the forecast period.

North America holds the major revenue chunk in the global kidney diseases diagnostics market. This is followed by Europe due to robust economic growth and investments in advanced diagnostic technologies. India, China and Vietnam from the APAC region are expected to demonstrate tremendous opportunities due to increased healthcare awareness, better household incomes and government aids to healthcare institutions. Rest of the world is expected to grow at a gradual CAGR and considerable market value in coming years.

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Beckman Coulter
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Siemens Healthineers
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • By Diagnosis
    • Blood Tests
    • Urine Tests
    • Imaging Tests
    • Others
  • By Treatment
    • Drug Class
      • ACE Inhibitors
      • Angiotensin-II Receptor Blockers
      • Diuretics
      • Other
    • Dialysis
    • Other

By End-User

  • Hospitals
  • Clinics
  • Diagnostic labs

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global Chronic Kidney Disease Diagnostics Market On The Basis Of Product Type, End User, and Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and Middle East and Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Chronic Kidney Disease Diagnostics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Chronic Kidney Disease Diagnostics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Chronic Kidney Disease Diagnostics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Chronic Kidney Disease Diagnostics Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. By Diagnosis
         1.1. Blood Tests
         1.2. Urine Tests
         1.3. Imaging Tests
         1.4. Others
        2. By Treatment
         2.1. Drug Class
          2.1.1. ACE Inhibitors
          2.1.2. Angiotensin-II Receptor Blockers
          2.1.3. Diuretics
          2.1.4. Other
         2.2. Dialysis
         2.3. Other

  • 8.   Chronic Kidney Disease Diagnostics Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Diagnostic labs

  • 9.   North America Chronic Kidney Disease Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Chronic Kidney Disease Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2022-2028

  • 11.   Europe Chronic Kidney Disease Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Chronic Kidney Disease Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott Laboratories
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. AbbVie Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Amgen Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Beckman Coulter
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. F. Hoffmann-La Roche Ltd
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GlaxoSmithKline Plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Pfizer, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Siemens Healthineers
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sysmex Corporation
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Teva Pharmaceutical Industries Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients